Kuby, J. (1994) Immunology, 2nd Ed., W.H. Freeman and Company, New York, pp. 473-474.* |
Chattergoon et al. Genetic Immunization: A New Era in Vaccines and Immune Therapeutics. FASEB Journal, vol. 11, pp. 753-763, Aug. 1997.* |
Zelphati, O., et al., Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes, Antisense Research and Development, 3:323-338, (1993). |
Milich et al. (1986). |
Shih et al. (1993). |
Haynes et al. (1993). |
Szmuness et al. (1982). |
Böhm et al. (1996). |
Jones, T., et al., “Synthetic oligodeoxynucleotiedes containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys”, Vaccine, 17:3065-3071, (1999). |
Karlin, S., et al., “Why is CpG Suppressed in the Genomes of Virtually All Small Eukaryotic Viruses but Not in Those of large Eukaryotic Virues?”, Journal of Virology, 2889-2897, (1994). |
Kataoka, T., et al., “Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of Mycbacterium vobis BCG”, Jpn. J. Cancer Res., 83:244-247, (1992). |
Krieg, A., et al., “CpG motifs in bacterial DNA trigger direct B-cell activation”, Nature, 374:546-549, (1995). |
Li, Z., et al., “Desmin sequence elements regulating skeletal muscle-specific expression in transgenic mice”, Development, 117:947-959, (1993). |
Liu, H., et al., “Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Machrophate colony-Stimulating Factor”, Blood, 92:3730-3736, (1998). |
McIntyre, K., et al., “A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation”, Antisense&Nucleic Acid Drug Development, 3:309-322, (1993). |
Manzel, L., et al., “Lack of Immune Stimulation by Immobilized CpG-Oligodeoxynucleotide”, Antisense&Nucleic Acid Drug Development, 9:459-464, (1999). |
Mojcik, C., et al., “Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific Manner”, Clinical Immunology and ImmunoPathology, 67:2:130-136, (1993). |
Pisetsky, D., et al., “Immunologic Consequences of Nucleic Acid Therapy”, Antisense&Nucleic Acid Drug Development, 5:219-225, (1995). |
Prince, A., et al., “Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus”, Vaccine, 15:916-919, (1997). |
Raz, E.,et al., “Intradermal gene immunization: The possible role of DNA utake in the induction of cellular immunity to viruses”, Proc. Natl. Acad. Sci., 91:9515-9523, (1994). |
Robinson, H., “Nucleic acid vaccines: an overview”, Vaccine, 15:8:785-787, (1997). |
Sands, H., et al., “Biodistribution and Metabolism of Internally 3H-Labeled Oligonucleotides. I. Comparison of a Phosphodiester and a Phosphorothioate”, The American Society for Pharmacology, 45:932-943, (1994). |
Stein, C., et al., “Antisense Oligonucleotides as Therapeutic Agents—Is the bullet Really Magical”, Science, 261:1004-1012, (1993). |
Thomsen, D., et al., “Promoter-regulatory region of the major immediate early gene of human cytomegalovirus”, Proc. Natl. Acad. Sci., 81:659-663, (1984). |
Tokunaga, T., et al., “Antitumor Activity of Deoxyribonucleic Acid Fraction From Mycobacterium bovis BCG. I. Isolation, Physicochemical Characterization, and Antitumor Activity”, JNCI, 72:955-962, (1984). |
Ulmer, J., et al., “Heterologous protection Against Influenza by Injection of DNA Encoding a Viral Protein”, Science, 259:1745-1749, (1993). |
Valenzuela, P., et al., “Synthesis and assembly of hepatitis B virus surface antigen particles in yeast”, Nature, 298:347-350, (1982). |
Wang, B., et al., “Gene inoculation generates immune responses against human immunodeficiency virus type 1”, Proc Natl. Acad. Sci., 90:4156-4160, (1993). |
Yaswen, P., et al., “Effects of Sequences of Thioated Oligonucleotides on cultured Human Mammary Epithelial Cells”, Antisense Research and Development, 3:67-77, (1993). |
Agrawal, S., et al., “Pharmacokinetics of Antisense Oligonucleotides”, Clin Pharmacokinet., 7-16, (1995). |
Cattaneo, R., et al., “Signals regulating hepatitis B surface antigen transcription”, Nature, 305:336-338, (1983). |
Cowdery, J., et al., Bacterial DNA Induces NK Cells to Produce IFN-γ In Vivo and Increases the Toxicity of Lipopolysaccharides, Bacterial DNA . . . , (1996). |
Davis, H.,et al., DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines, Proc Natl Acad, Sci, 93:7213-7218, (1996). |
Fujieda, S., et al., “Effect of OK-432 on Cytotoxic Activity in Cancer patients without Tumor Burden”, Anticancer Research, 12:1941-1946, (1992). |
Fuller, D., et al., “Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene Gun-mediated DNA vaccination”, J. Med. Primates, 25:236-241, (1996). |
Fynan, E., et al., “DNA vaccines: Protective immunizations by parentaeral, mucosal, and gene-gun inoculations”, Proc. Natl. Acad. Sci., 90:11478-11482, (1993). |
Gao, W., et al., “Phosphorothioate Oligonucleotides are inhibitors of human DNA polymerases and Rnase H: implications for antisense technology”, 223-229, (1991). |
Davis, H.,et al., “Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression” Human Gene Therapy, 4: 151-159, (1993). |
Davis, H.,et al., “DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibod” Human Molecular Genetics, 2:1847-1852, (1993). |
Lutynski R and Juszczyk R, “The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants” Folia Med. Cracov., 38: 63-68, (1997) Abstract. |
Whalen, R., et al., DNA Vaccines for Emerging Infectious Diseases: What if?, “Emerging Infectious Diseases”, (1996), 2:3:168-175. |
Calandra G.B. et al., Recommendations for Prevention of Hepatitis B with Vaccine, Hepatitis B Vaccines in Clinical Practice, Merck Research Laboratories, pp. 1-16, 1993. |
Chambon, P., ADN: sur la piste du vaccine génétique, Sciences et Avenir, Sep. 1993, pp. 22-25. |
Fujisawa, T. et al., Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen., J Pediatr Gastroenterol Nutr, Oct. 1996, 23(3):270-4. |
Hayes, J.R. et al., Particle-mediated nucleic acid immunization, Journal of Biotechnology 44, 1996, pp. 37-42. |
Kuhöber, A., et al. DNA Immunization Induces Antibody and Cytotoxic T Cell Responses to Hepatitis B Core Antigen in H-2b Mice, The American Association of Immunologists, 1996, pp. 3687-3695. |
LeBorgne, S. et al., In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen, Virology 240, 304-315, 1998, Article No. VY978942. |
Lee, P.I. et al., Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen, J Pediatr, May 1995, 126(5 Pt 1):716-21. |
Wolff et al., Direct Gene Transfer into Muse Muscle in Vivo, Science, vol. 247, Mar. 1990, pp. 1465-1468. |
Raz, E. et al., “Systemic immunological effects of cytokine genes injected into skeletal muscle”, Proc. Natl. Acad. Sci. USA, May 1993, pp. 4523-4527, vol. 90. |
Tang, D. et al., “Genetic immunization is a simple method for eliciting an immune response”, Nature, Mar. 12, 1992, pp. 152-154, vol. 356. |